Wells Fargo & Company Increases ResMed (NYSE:RMD) Price Target to $270.00

ResMed (NYSE:RMD) had its price objective boosted by equities research analysts at Wells Fargo & Company from $265.00 to $270.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 4.75% from the company’s current price.

A number of other equities analysts also recently weighed in on RMD. KeyCorp reissued an “overweight” rating and set a $302.00 price target on shares of ResMed in a research report on Friday. Morgan Stanley set a $305.00 price target on ResMed in a research note on Friday, October 31st. Stifel Nicolaus raised their price target on ResMed from $260.00 to $265.00 and gave the company a “hold” rating in a report on Friday. Piper Sandler lifted their price objective on shares of ResMed from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of ResMed in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and an average target price of $297.91.

ResMed Trading Up 0.1%

ResMed stock opened at $257.76 on Friday. ResMed has a one year low of $199.92 and a one year high of $293.81. The company has a market cap of $37.62 billion, a price-to-earnings ratio of 25.50, a P/E/G ratio of 1.73 and a beta of 0.88. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.89 and a quick ratio of 2.13. The firm has a 50-day moving average of $251.04 and a 200-day moving average of $263.30.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The firm had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a return on equity of 25.68% and a net margin of 27.53%.The business’s revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company earned $2.43 earnings per share. On average, equities analysts expect that ResMed will post 9.47 earnings per share for the current fiscal year.

Insider Activity at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $248.83, for a total value of $497,660.00. Following the completion of the sale, the director owned 66,773 shares of the company’s stock, valued at $16,615,125.59. The trade was a 2.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Witte Jan De sold 2,055 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total transaction of $524,025.00. Following the transaction, the director directly owned 4,261 shares in the company, valued at $1,086,555. This represents a 32.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 21,594 shares of company stock worth $5,403,495. Corporate insiders own 0.65% of the company’s stock.

Institutional Investors Weigh In On ResMed

Several institutional investors have recently made changes to their positions in RMD. Norges Bank acquired a new position in ResMed in the 2nd quarter valued at $306,452,000. First Trust Advisors LP increased its position in shares of ResMed by 285.1% in the third quarter. First Trust Advisors LP now owns 445,198 shares of the medical equipment provider’s stock worth $121,864,000 after purchasing an additional 329,588 shares during the period. Marshall Wace LLP raised its stake in ResMed by 2,373.1% in the third quarter. Marshall Wace LLP now owns 310,987 shares of the medical equipment provider’s stock valued at $85,126,000 after purchasing an additional 298,412 shares in the last quarter. Nordea Investment Management AB lifted its position in ResMed by 37.2% during the fourth quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock worth $262,027,000 after purchasing an additional 294,124 shares during the period. Finally, Vanguard Group Inc. grew its stake in ResMed by 1.6% during the third quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider’s stock worth $5,211,940,000 after buying an additional 293,515 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

ResMed News Roundup

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat consensus — GAAP diluted EPS of $2.68 (non‑GAAP $2.81) vs. Street estimates ~ $2.68, revenue $1.423B (+11% YoY), 320 bps gross‑margin improvement and $340M operating cash flow. These metrics support near‑term earnings credibility and cash generation. Read More.
• Positive Sentiment: Board declared a quarterly cash dividend of $0.60 per share (record Feb 12; payable Mar 19), signaling capital return commitment and supporting income investors. Read More.
• Positive Sentiment: Product/innovation catalysts: FDA cleared an AI‑enabled device (“Smart Comfort”) to personalize CPAP settings — strengthens digital/AI positioning and could boost adherence and recurring device/accessory demand. Read More.
• Positive Sentiment: Wells Fargo nudged its price target to $270 (from $265) with an “equal weight” rating — a modest analyst lift that implies limited near‑term upside from that shop. Read More.
• Neutral Sentiment: Analyst landscape remains mixed but generally favorable — several firms maintain outperform/buy views and available median targets sit materially above current price, leaving room for differing investor expectations. Read More.
• Neutral Sentiment: Company hosted the Q2 webcast and transcripts are posted — useful for hearing management’s guide/comments on demand, supply and margin outlook. Read More.
• Negative Sentiment: Expenses rose: SG&A and R&D both increased (~12% YoY) and the company recorded $6M in restructuring charges; higher operating costs could pressure margins if growth slows. Read More.
• Negative Sentiment: Notable insider selling activity was reported in recent months (multiple sales by senior executives), which some investors view as a modest governance/conviction caution. Read More.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.